Literature DB >> 18630462

Differences in expression of tumor markers between pre- and postmenopausal women with invasive cervical cancer.

Dan Hellberg1, Tibor Tot, Ulf Stendahl.   

Abstract

UNLABELLED: THE AIM of the present study was to investigate the differences in the expression of tumor markers in squamous cell and in adenomatous carcinomas in pre- and postmenopausal women, respectively. PATIENTS AND METHODS: The study population comprised 53 premenopausal and 107 postmenopausal women. Thirty-four tumors were adenomatous (n=31) or adenosquamous carcinomas (n=3), distributed between 13 premenopausal and 21 postmenopausal women. The remaining 126 squamous cell carcinomas were diagnosed in 40 pre- and 86 postmenopausal women. Expression of ten tumor markers of possible clinical importance in cervical cancer was evaluated.
RESULTS: Expression of three tumor markers, p53 (>0% vs. 0%), p27 (> or =20% vs. <20%) and cyclooxygenase-2 (COX-2) (high intensity vs. moderate/none) differed significantly between pre- compared to postmenopausal women with squamous cell (p27; 54% vs. 72%, p=0.009) or adenomatous carcinomas (p53; 8% vs. 63%, p=0.006 and COX-2; 46% vs. 20%, p=0.03). All results were adjusted for clinical cancer stage.
CONCLUSION: The unusual age-specific incidence curve in cervical cancer has rarely been related to expression of tumor markers. Age-related differences in expression of tumor markers could reflect some age-related different biological mechanisms in cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18630462

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Expression of matrix metalloproteinase-2 and 9 in cervical intraepithelial neoplasia and cervical carcinoma among different age groups of premenopausal and postmenopausal women.

Authors:  Arnab Ghosh; Anuradha Moirangthem; Rabindranath Dalui; TapanKumar Ghosh; Arghya Bandyopadhyay; Anindya Dasgupta; Uma Banerjee; Narayan Jana; Anupam Basu
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-08       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.